Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)

NEXT STORY
NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study
PREV STORY
Global Oncology/Cancer Drugs Market To Grow At CAGR of 7.6% During 2020 To 2028
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Advanced Accelerator Applications Announces Positive CHMP Opinion Recommending Approval of Lutetium 177Lu Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors

SAINT-GENIS-POUILLY, France, July 21, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA ...

author_avatar
NASDAQ Market News

Antios Therapeutics Appoints Patrick T. Higgins to Board of Directors

author_avatar
NASDAQ Market News

GeoVax and Virometix to Collaborate on Immunotherapy Program for HPV Infections and Related Cancers

GeoVax Continues Expansion of International Collaborative Efforts for its Unique MVA-VLP Vaccine Technology ATLANTA, ...

author_avatar
NASDAQ Market News